• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体及其片段作为抗癌剂。

Antibodies and their fragments as anti-cancer agents.

作者信息

Schaedel Oren, Reiter Yoram

机构信息

Faculty of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel.

出版信息

Curr Pharm Des. 2006;12(3):363-78. doi: 10.2174/138161206775201983.

DOI:10.2174/138161206775201983
PMID:16454750
Abstract

The recent developments in the field of recombinant DNA, protein engineering and cancer biology, have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, to regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals; monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and high affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. Upon binding to the Fc Receptor on effector cells, the crystallisable fragment (Fc) region elicits the onslaught of Antigen Dependent Cell-mediated Cytotoxicity (ADCC) and the plasma-native Complement Dependent Cytotoxicity (CDC) response and apoptosis. The progenitor form of the antibody can evolve in to a tailored therapeutic molecule with the help of recombinant DNA technology. Recombinant antibodies may be linked to potent toxins or radio-labeled fragments, conferring a high killing capability. Other recombinant techniques such as ADEPT, conjugate the specificity of antibodies to a prodrug-catalytic subunit thus creating a high local concentration of an activated chemotherapeutic. Antibodies can be used to recruit the adaptive immune response by binding the antibody fragment to a recombinant MHC molecule displaying a highly immunogenic peptide. Apart from their therapeutic capabilities antibodies are powerful detection tools as observed in the operating theater in a procedure known as Radio-immuno-guided Surgery (RIGS).

摘要

重组DNA、蛋白质工程和癌症生物学领域的最新进展,使我们深入了解了许多与癌症相关的机制。此外,新技术还催生了一些工具,能够明确区分恶性转化细胞和正常细胞。这种认识为合理设计新时代的药物——单克隆抗体及其片段——铺平了道路。抗体能够以高亲和力特异性地识别抗原,利用这些特性进一步通过特异性识别癌细胞群体的外源抗原来靶向癌细胞。抗体的结构因其功能位点而具有可塑性。当与效应细胞上的Fc受体结合时,可结晶片段(Fc)区域引发抗原依赖性细胞介导的细胞毒性(ADCC)、天然补体依赖性细胞毒性(CDC)反应及细胞凋亡。借助重组DNA技术,抗体的原始形式可演变成一种定制的治疗分子。重组抗体可与强效毒素或放射性标记片段相连,从而具备强大的杀伤能力。其他重组技术,如抗体导向酶前体药物疗法(ADEPT),将抗体的特异性与前体药物催化亚基结合,从而在局部产生高浓度的活化化疗药物。通过将抗体片段与展示高免疫原性肽段的重组MHC分子结合,抗体可用于激发适应性免疫反应。除了具有治疗能力外,抗体还是强大的检测工具,如在手术室中通过放射免疫导向手术(RIGS)所体现的那样。

相似文献

1
Antibodies and their fragments as anti-cancer agents.抗体及其片段作为抗癌剂。
Curr Pharm Des. 2006;12(3):363-78. doi: 10.2174/138161206775201983.
2
Novel antibodies as anticancer agents.新型抗体作为抗癌药物。
Oncogene. 2007 May 28;26(25):3714-33. doi: 10.1038/sj.onc.1210372.
3
Recombinant antibodies for the diagnosis and treatment of cancer.用于癌症诊断和治疗的重组抗体。
Mol Biotechnol. 2003 Sep;25(1):1-17. doi: 10.1385/MB:25:1:1.
4
Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.使用偶联和非偶联单克隆抗体进行人类癌症检测与免疫治疗。
Anticancer Res. 1996 Mar-Apr;16(2):661-74.
5
Immunotoxin therapy of cancer.癌症的免疫毒素疗法。
Nat Rev Cancer. 2006 Jul;6(7):559-65. doi: 10.1038/nrc1891.
6
Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.用于直接抗肿瘤治疗和癌细胞特异性递送化疗药物的基因工程单克隆抗体。
Curr Pharm Des. 2000 Feb;6(3):261-76. doi: 10.2174/1381612003401109.
7
Recombinant immunotoxins in targeted cancer cell therapy.靶向癌细胞治疗中的重组免疫毒素
Adv Cancer Res. 2001;81:93-124. doi: 10.1016/s0065-230x(01)81003-4.
8
Recombinant antibody fragments and immunotoxin fusions for cancer therapy.用于癌症治疗的重组抗体片段和免疫毒素融合物。
In Vivo. 2000 Jan-Feb;14(1):21-7.
9
Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors.重组免疫毒素与重定向杀伤细胞:利用工程化抗体片段实现细胞毒性效应物的肿瘤特异性靶向
Cancer Immunol Immunother. 2004 Mar;53(3):217-26. doi: 10.1007/s00262-003-0482-8. Epub 2003 Dec 24.
10
Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.通过肿瘤特异性抗体介导的单链I类主要组织相容性复合体-肽复合物靶向作用募集细胞毒性T淋巴细胞活性。
J Immunol. 2002 Sep 15;169(6):2988-96. doi: 10.4049/jimmunol.169.6.2988.

引用本文的文献

1
Characterization of single chain antibody targets through yeast two hybrid.通过酵母双杂交技术鉴定单链抗体的靶标。
BMC Biotechnol. 2010 Aug 22;10:59. doi: 10.1186/1472-6750-10-59.
2
Genetic control of wayward pluripotent stem cells and their progeny after transplantation.移植后任性的多能干细胞及其后代的遗传控制
Cell Stem Cell. 2009 Apr 3;4(4):289-300. doi: 10.1016/j.stem.2009.03.010.
3
Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation.通过酵母联合表达和体外化学酶促糖基化对人IgG1-Fc进行糖基工程改造。
Biochemistry. 2008 Sep 30;47(39):10294-304. doi: 10.1021/bi800874y. Epub 2008 Sep 5.
4
Antibody-cytokine fusion proteins: applications in cancer therapy.抗体-细胞因子融合蛋白:在癌症治疗中的应用
Expert Opin Biol Ther. 2008 May;8(5):609-32. doi: 10.1517/14712598.8.5.609.
5
Emerging treatments and gene expression profiling in high-risk medulloblastoma.高危髓母细胞瘤的新兴治疗方法与基因表达谱分析
Paediatr Drugs. 2007;9(2):81-96. doi: 10.2165/00148581-200709020-00002.